Although alpelisib monotherapy yielded tumor responses in heavily pretreated ER+HER2− advanced breast cancer in phase I (26) and phase II (32) studies, the greatest therapeutic response tested was observed when alpelisib was administered in combination with fulvestrant (33). This evidence concerns the gene ESR1 and breast carcinoma.